Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Amelie Boquoi, MD, Aristoteles Giagounidis, Hartmut Goldschmidt, MD, Michael Heinsch, MD, Mathias J Rummel, MD PhD, Nicolaus Kroeger, David Lopez y Niedenhoff, MD, C. Matthias Wilk, MD, Ingrida Savickaite, MD, Elias K Mai, MD, Carlo Aul, MD, Judith Strapatsas, MD, Ariane Dienst, MD, Mustafa Kondakci, MD, Rainer Haas, MD, Guido Kobbe, Roland Fenk, MD PhD

Blood (2018) 132 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2018-99-110977

Published: 2018

Journal Articles

Changes of the Niche of Erythropoiesis Appear to Contribute to Severe Transfusion-Dependent Anemia in a Significant Proportion of Patients with Myelodysplastic Syndromes

Guntram Buesche, MD, Aristoteles Giagounidis, MD PhD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD Prof., Arnold Ganser, MD, Carlo Aul, MD, Hans Heinrich Kreipe, MD

Blood (2015) 126 (23): 4114.

https://doi.org/10.1182/blood.V126.23.4114.4114

Published: 2015

Journal Articles

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Christian T. Dietz, PhD, Alice Charlotte Fabarius, PhD, Michael Lauseker, PhD, Susanne Saussele, Lida Kalmanti, Sébastien Rinaldetti, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martine Jotterand, Alois Gratwohl, Axel R. Zander, Professor, Nicolaus Kröger, Dietrich W. Beelen, MD, Jürgen Novotny, Christoph Nerl, Christof Scheid, MD PhD, Karsten Spiekermann, Jiri Mayer, MD, Herbert G. Sayer, Christiane Falge, Donald Bunjes, MD, Hartmut Döhner, Prof. Dr., Arnold Ganser, Peter Brossart, MD, Rainer Schwerdtfeger, Herrad Baumann, Rolf Kuse, Hans Walter Lindemann, MD, Matthias Bormann, Bernd Hertenstein, MD, Gabriela M. Baerlocher, Carlo Aul, MD, Peter Staib, Matthias Edinger, MD, Michael Schatz, Axel A Fauser, Renate Arnold, MD, Dieter K. Hossfeld, MD, Hans-Jochem Kolb, Susanne Schnittger, PhD, Martin C. Müller, MD, Andreas Reiter, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Joerg Hasford, Michele Baccarani, Ruediger Hehlmann, MD

Blood (2015) 126 (23): 1581.

https://doi.org/10.1182/blood.V126.23.1581.1581

Published: 2015

Journal Articles

Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group

Heiko Becker, MD, Stefan Suciu, PhD, Björn Rüter, MD, Uwe Platzbecker, MD, PhD, Aristoteles Giagounidis, MD, Dominik Selleslag, MD, Boris Labar, MD, PhD, Ulrich Germing, MD, Helmut R. Salih, MD, Petra Muus, MD, PhD, Karl-Heinz Pflüger, MD, Anne Hagemeijer, MD, PhD, Hans-Eckart Schaefer, MD, Frédéric Baron, MD, PhD, Arnold Ganser, MD, Carlo Aul, MD, Theo de Witte, MD, Pierre W. Wijermans, MD, Michael Lübbert, MD

Blood (2013) 122 (21): 1452.

https://doi.org/10.1182/blood.V122.21.1452.1452

Published: 2013

Journal Articles

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Guntram Buesche, MD, Aristoteles Giagounidis, MD, Gudrun Göhring, Brigitte Schlegelberger, Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2012) 120 (21): 2826.

https://doi.org/10.1182/blood.V120.21.2826.2826

Published: 2012

Journal Articles

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Guntram Buesche, M.D., Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2011) 118 (21): 3819.

https://doi.org/10.1182/blood.V118.21.3819.3819

Published: 2011

Journal Articles

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Blood (2011) 118 (21): 2773.

https://doi.org/10.1182/blood.V118.21.2773.2773

Published: 2011

Journal Articles

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Guntram Buesche, MD, Stephanie Dieck, Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Robert Knight, MD, Carlo Aul, MD, Hans Kreipe, MD

Blood (2009) 114 (22): 3800.

https://doi.org/10.1182/blood.V114.22.3800.3800

Published: 2009

Journal Articles

Risk Factors for Disease Progression in del(5q) MDS Patients Treated with Lenalidomide.

Aristoteles A. Giagounidis, MD, Sabine Haase, Uwe Platzbecker, MD PhD, Ulrich Germing, MD PhD, Vera Lohrbacher, Gerhard Ehninger, MD PhD, Carlo Aul, MD PhD

Blood (2007) 110 (11): 1460.

https://doi.org/10.1182/blood.V110.11.1460.1460

Published: 2007

Journal Articles

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Claudia Schoch, MD, Torsten Haferlach, MD, Hubert L. Serve, MD, Joachim Kienast, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Joelle Tchinda, MD, Albrecht Reichle, MD, Peter Staib, MD, Wolf-Dieter Ludwig, MD, Carlo Aul, MD, Maria Cristina Sauerland, Dipl Math, Achim Heinecke, PhD, Bernhard Josef Wormann, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 1977.

https://doi.org/10.1182/blood.V108.11.1977.1977

Published: 2006

Journal Articles

Lenalidomide Is Likely To Improve Overall Survival in Patients with del(5q) Myelodysplastic Syndrome with a Complex Karyotype.

Aristoteles A. Giagounidis, MD, Sabine Haase, Ulrich Germing, MD PhD, Gundula Göhring-Michaelsen, Brigitte Schlegelberger, MD PhD, Carlo Aul, MD PhD

Blood (2006) 108 (11): 4860.

https://doi.org/10.1182/blood.V108.11.4860.4860

Published: 2006

Journal Articles

Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.

Detlef Haase, MD, PhD, Ulrich Germing, MD, PhD, Julie Schanz, MD, Michael Pfeilstoecker, MD, PhD, Barbara Hildebrandt, PhD, Michael Luebbert, MD, PhD, Aristoteles Giagounidis, MD, Carlo Aul, MD, PhD, Lorenz Truemper, MD, PhD, Thomas Mueller, PhD, Peter Valent, MD, PhD, Norbert Gattermann, MD, PhD, Christa Fonatsch, PhD, Otto Krieger, MD, PhD, Reinhard Stauder, MD, Christian Steidl, MD

Blood (2006) 108 (11): 252.

https://doi.org/10.1182/blood.V108.11.252.252

Published: 2006

Journal Articles

New and Comprehensive Cytogenetic Prognostication and Categorization in MDS.

Detlef Haase, MD, PhD, Ulrich Germing, MD, PhD, Julie Schanz, MD, Michael Pfeilstoecker, MD, PhD, Thomas Noesslinger, MD, Barbara Hildebrandt, PhD, Andrea Kuendgen, MD, Michael Luebbert, MD, PhD, Aristoteles Giagounidis, MD, Carlo Aul, MD, PhD, Lorenz Truemper, MD, PhD, Thomas Mueller, PhD, Peter Valent, MD PhD, Christa Fonatsch, MD, PhD, Christian Steidl, MD

Blood (2006) 108 (11): 248.

https://doi.org/10.1182/blood.V108.11.248.248

Published: 2006

Journal Articles

Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML).

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Claudia Schoch, MD, Torsten Haferlach, MD, Hubert L. Serve, MD, Joachim Kienast, MD, Susanne Schnittger, PhD, Wolfgang Kern, MD, Joelle Tchinda, PhD, Albrecht Reichle, MD, Peter Staib, MD, Wolf-Dieter Ludwig, MD, Carlo Aul, MD, Maria-Cristina Sauerland, Achim Heinecke, PhD, Bernhard Woermann, MD, Wolfgang Hiddemann, MD

Blood (2005) 106 (11): 272.

https://doi.org/10.1182/blood.V106.11.272.272

Published: 2005

Journal Articles

The Influence of Age and Gender on the Prognostic Impact of Karytoypic Subgroups in Myelodysplastic Syndromes - a Multicenter Analysis.

Thomas Noesslinger, MD, Ulrich Germing, MD, PD, Barbara Hildebrandt, MD, Claudia Strupp, MD, Manuel Aivado, MD, Detlef Haase, MD, Julie Schanz, MD, Friedrich Wimazal, MD, Wolfgang Sperr, MD, Valent Peter, MD, Lubbert Michael, MD, PD, Otto Krieger, MD, Norbert Gattermann, MD, Aristoteles Giagounidis, MD, Heinz Tuchler, Rainer Haas, MD, Carlo Aul, MD, Michael Pfeilstocker, MD, PD

Blood (2004) 104 (11): 1448.

https://doi.org/10.1182/blood.V104.11.1448.1448

Published: 2004

Journal Articles

Long-Term Follow-Up of a Randomized Phase III Multicenter Study Comparing a Standard Versus an Intensified Conditioning Regimen for High-Dose Chemotherapy in Patients with Multiple Myeloma.

Roland Fenk, MD, Peter Schneider, MD, Martin Kropff, MD, Ali-Nuri Huenerlituerkoglu, MD, Ulrich Steidl, MD, Carlo Aul, MD, Axel Heyll, MD, Rainer Haas, MD, Guido Kobbe, MD

Blood (2004) 104 (11): 945.

https://doi.org/10.1182/blood.V104.11.945.945

Published: 2004

Journal Articles

Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies.

Sabine Knipp, MD, Barbara Hildebrandt, PhD, Aristoteles A.N. Giagounidis, MD, Guido Kobbe, MD, Rainer Haas, MD, Carlo Aul, MD, Norbert Gattermann, MD, Ulrich Germing, MD

Blood (2004) 104 (11): 72.

https://doi.org/10.1182/blood.V104.11.72.72

Published: 2004

Journal Articles

High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRA TM ).

Razelle Kurzrock, MD, Pierre Fenaux, MD, Azra Raza, MD, Ghulam Mufti, MD, Carlo Aul, MD, Ulrich Germing, MD, Rene Kerstens, MD, Peter DePorre, MD

Blood (2004) 104 (11): 68.

https://doi.org/10.1182/blood.V104.11.68.68

Published: 2004

Journal Articles

Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α.

Aristoteles A.N. Giagounidis, MD, Sabine Haase, Ulrich Germing, MD, PhD, Claudia Schoch, MD, PhD, Brigitte Schlegelberger, PhD, Ludwig Wilkens, PhD, Guntram Büsche, MD, Hans H. Kreipe, MD, PhD, Manuel Aivado, MD, Michael Lübbert, MD, PhD, Arnold Ganser, MD, PhD, Carlo Aul, MD, PhD

Blood (2004) 104 (11): 4729.

https://doi.org/10.1182/blood.V104.11.4729.4729

Published: 2004

NARROW

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Changes of the Niche of Erythropoiesis Appear to Contribute to Severe Transfusion-Dependent Anemia in a Significant Proportion of Patients with Myelodysplastic Syndromes

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Risk Factors for Disease Progression in del(5q) MDS Patients Treated with Lenalidomide.

Changes in the Hierarchy of Risk Factors with Older Age in De-Novo Acute Myeloid Leukemia (AML).

Lenalidomide Is Likely To Improve Overall Survival in Patients with del(5q) Myelodysplastic Syndrome with a Complex Karyotype.

Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS.

New and Comprehensive Cytogenetic Prognostication and Categorization in MDS.

Double Induction Containing Two Courses Versus One Course of High- Dose AraC/ Mitoxantrone (HAM) and Autologous Stem Cell Transplantation Versus Prolonged Maintenance for Acute Myeloid Leukemia (AML).

The Influence of Age and Gender on the Prognostic Impact of Karytoypic Subgroups in Myelodysplastic Syndromes - a Multicenter Analysis.

Long-Term Follow-Up of a Randomized Phase III Multicenter Study Comparing a Standard Versus an Intensified Conditioning Regimen for High-Dose Chemotherapy in Patients with Multiple Myeloma.

Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies.

High-Risk Myelodysplastic Syndrome (MDS): First Results of International Phase 2 Study with Oral Farnesyltransferase Inhibitor R115777 (ZARNESTRA TM ).

Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only